# Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome

> **NCT00266656** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 69 (actual)

## Conditions studied

- Turner Syndrome

## Interventions

- **DRUG:** Humatrope

## Key facts

- **NCT ID:** NCT00266656
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2017-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266656, "Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00266656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*